Mereo BioPharma Group plc Cash Flow-to-Debt Ratio
Mereo BioPharma Group plc cash flow-to-debt ratio. Mereo BioPharma Group plc (MAH0) has a Cash Flow-to-Debt Ratio of -1.54x as of December 2025, meaning its operating cash flow of €-7.68 Million could theoretically repay -2% of its total liabilities (€5.00 Million) in one year. Check Mereo BioPharma Group plc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Mereo BioPharma Group plc (2016–2025)
Cash flow-to-debt ratio of Mereo BioPharma Group plc from 2016 to 2025. Historical debt coverage capacity for Mereo BioPharma Group plc across 10 annual periods. Check Mereo BioPharma Group plc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Mereo BioPharma Group plc Cash Flow-to-Debt Ratio by Year (2016–2025)
Mereo BioPharma Group plc cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Mereo BioPharma Group plc. For the full cash flow conversion analysis, see Mereo BioPharma Group plc (MAH0) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.19x | €-30.97 Million | €5.00 Million | ▼ -190.9% |
| 2024 | -2.13x | €-32.83 Million | €15.42 Million | ▼ -60.8% |
| 2023 | -1.32x | €-21.13 Million | €15.96 Million | ▲ +10.6% |
| 2022 | -1.48x | €-38.82 Million | €26.21 Million | ▼ -986.0% |
| 2021 | -0.14x | €-5.24 Million | €38.41 Million | ▲ +62.5% |
| 2020 | -0.36x | €-28.34 Million | €77.92 Million | ▲ +63.4% |
| 2019 | -0.99x | €-45.93 Million | €46.19 Million | ▼ -48.3% |
| 2018 | -0.67x | €-23.14 Million | €34.51 Million | ▲ +29.4% |
| 2017 | -0.95x | €-32.15 Million | €33.85 Million | ▲ +76.0% |
| 2016 | -3.95x | €-29.66 Million | €7.51 Million | — |